The DELIVER-MS study seeks to answer the important question: does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy, and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide overall treatment philosophy and will be applicable not only to a wide range of existing therapies, but also to new therapies. This will meet a significant unmet need in patient decision making and aid the decision for medication approval by third parties.
DELIVER-MS: Determining the Effectiveness of Early Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis
DELIVER-MS work highlighted with a Neurology podcast and editorial titled Making public and patient involvement in clinical trials more than aspirational (https://cp.neurology.org/content/10/3/188). This commentary...Read More
Based on feedback from DELIVER-MS investigators and participants, who have told us how helpful they find the www.deliver-ms.com website, we have developed a QR...Read More